Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIN2D | O15399 | 1/20 | 0.64 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.64 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.64 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.64 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.64 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.64 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.64 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | RAD52 | P43351 | 1/20 | 0.43 |
| ▸ | PGR | P06401 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2764154 | 0.90 | ALDH1A1 (0.51) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1352813 | 0.86 | GRIN2D (0.75) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL1939374 | 0.83 | GRIN2D (0.47) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL31354841 | 0.82 | LMNA (0.59) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL2710126 | 0.81 | GRIN2D (0.68) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL25458202 | 0.78 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL13286757 | 0.78 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL294311 | 0.78 | GRIN2D (1.00) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL22926703 | 0.78 | GRIN2D (0.64) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B | |
| SCHEMBL181479 | 0.78 | GRIN2D (0.62) | GRIN2DGRIN3BGRIN1GRIN2AGRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250154114-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT DEVICE, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | TOSOH CORPORATION (JP) | 2025-05-15 | — | — | US | disclosed |
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | ARISAN THERAPEUTICS INC. (US) | 2025-03-04 | — | — | US | disclosed |
| CN-118696625-A | Material for metal patterning, heterocyclic compound, thin film for metal patterning, organic electroluminescent element, electronic device, and method for forming metal pattern | 东曹株式会社 | 2024-09-24 | — | — | CN | disclosed |
| EP-3405183-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | Arisan Therapeutics Inc. (US) | 2018-11-28 | — | — | EP | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
| WO-2017127306-A1 | ADAMATANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTION | ARISAN THERAPEUTICS (US) | 2017-07-27 | — | — | WO | disclosed |
| EP-1989177-B1 | AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME | UNIV GIESSEN JUSTUS LIEBIG (DE) | 2012-08-01 | — | — | EP | disclosed |
| US-20090299096-A1 | Amidoadamantanes and Method for Producing the Same | JUSTUS-LIEBIG-UNIVERSITAT GIESSEN (DE) | 2009-12-03 | — | — | US | disclosed |
| EP-1989177-A1 | AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME | Justus-Liebig-Universität Giessen (DE) | 2008-11-12 | — | — | EP | disclosed |
| WO-2007101535-A1 | AMIDOADAMANTANES AND METHOD FOR PRODUCING THE SAME | JUSTUS-LIEBIG-UNIVERSITÄT GIESSEN (DE) | 2007-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12240857-B2 | Adamantane derivatives for the treatment of filovirus infection | IFNAR1, MEP1B, MEP1A | GRIN2D 3988/4885GRIN3B 2211/4885GRIN1 1774/4885 |
| US-20090299096-A1 | Amidoadamantanes and Method for Producing the Same | ADORA3, TAAR5, ADORA1 | GRIN2D 1051/4885GRIN3B 1517/4885GRIN1 1026/4885 |
| US-20250154114-A1 | MATERIAL FOR METAL PATTERNING, HETEROCYCLIC COMPOUND, THIN FILM FOR METAL PATTERNING, ORGANIC ELECTROLUMINESCENT DEVICE, ELECTRONIC DEVICE, AND METHOD FOR FORMING METAL PATTERN | NES, L1CAM, MNS1 | GRIN2D 293/4885GRIN3B 1540/4885GRIN1 207/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.